[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 385
Citations 0
Clinical Trials Update
May NaN, 2016

CABG Delivers Survival Benefit in Ischemic Cardiomyopathy

JAMA. 2016;315(20):2159. doi:10.1001/jama.2016.6212

Among patients who had coronary artery bypass graft (CABG) procedures in addition to medical therapy for coronary artery disease, heart failure, and severe left ventricular systolic dysfunction, the rate of death from any cause was 16% lower over a decade compared with patients treated with medical therapy alone (Velazquez EJ et al. N Engl J Med. 2016;374:1511-1520). The significant survival benefit was evident only in the long-term follow-up of the previously published Surgical Treatment for Ischemic Heart Failure (STICH) trial (Velazquez EJ et al. N Engl J Med. 2011;364:1607-1616); at approximately 5 years, there was no significant difference in all-cause mortality between those who had surgical revascularization vs those who had only medical therapy.

First Page Preview View Large
First page PDF preview
First page PDF preview